Combination treatments with sonic hedgehog inhibitors

US10220091B2 · kind B2 · utility

Assignee

• The General Hospital Corporation · US

Inventors

• Francesco Sabbatino · Boston, US
• Yangyang Wang · Scarsdale, US
• Xinhui Wang · Poughkeepsie, US
• Steven Isakoff · Brookline, US
• Cristina Ferrone · Boston, US
• Joe Schwab · Boston, US
• Soldano Ferrone · Buffalo, US

Key dates

• Filing date: Apr 3, 2014
• Grant date: Mar 5, 2019
• Expiry date: Apr 3, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/15043
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods for treating cancer using a combination of an inhibitor of the sonic hedgehog signaling pathway (e.g., LDE225) with radiation and a tumor antigen-specific monoclonal antibody (e.g., heat shock protein (HSP) glucose regulated protein of 94000 daltons (Grp94)-specific mAb W9, or chondroitin sulfate proteoglycan 4 (CSPG4)-targeted mAbs), or with a BRAF inhibitor, e.g., in BRAF inhibitor resistant cancers.